{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:57:00Z","timestamp":1781225820804,"version":"3.54.1"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04316-0","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:35:22Z","timestamp":1777271722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovative approaches in the treatment of hematologic malignancies: the role of CRISPR-engineered microbiomes along the gut-immune axis in immunotherapy development"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7105-1161","authenticated-orcid":false,"given":"Chou-Yi","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-5617","authenticated-orcid":false,"given":"Amr Ali Mohamed","family":"Abdelgawwad El-Sehrawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer Saleem","family":"Alshkarchy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir S.","family":"Abdul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbulakshmi","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya Priyadarshini","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0741-6211","authenticated-orcid":false,"given":"Amirali","family":"Ebrahimpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeganeh","family":"Khazaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"4","key":"4316_CR1","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","volume":"28","author":"AV Finck","year":"2022","unstructured":"Finck AV, et al. Engineered cellular immunotherapies in cancer and beyond. Nat Med. 2022;28(4):678\u201389.","journal-title":"Nat Med"},{"issue":"7","key":"4316_CR2","doi-asserted-by":"publisher","first-page":"7069","DOI":"10.1007\/s11033-022-07147-0","volume":"49","author":"S Quazi","year":"2022","unstructured":"Quazi S. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy. Mol Biol Rep. 2022;49(7):7069\u201377.","journal-title":"Mol Biol Rep"},{"key":"4316_CR3","first-page":"257","volume":"55","author":"W Yan","year":"2026","unstructured":"Yan W, et al. Synergistic fusion of CD47, VE-cadherin and mussel adhesion protein promotes endothelialization and suppresses inflammation in vascular stents. Bioact Mater. 2026;55:257\u201370.","journal-title":"Bioact Mater"},{"issue":"5","key":"4316_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/bjh.15851","volume":"185","author":"TI Jensen","year":"2019","unstructured":"Jensen TI, Axelgaard E, Bak RO. Therapeutic gene editing in haematological disorders with CRISPR\/Cas9. Br J Haematol. 2019;185(5):821\u201335.","journal-title":"Br J Haematol"},{"issue":"1","key":"4316_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12929-025-01208-9","volume":"33","author":"Y Chen","year":"2026","unstructured":"Chen Y, et al. Microbiome modulation of tumorigenesis and immune responses. J Biomed Sci. 2026;33(1):4.","journal-title":"J Biomed Sci"},{"key":"4316_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2025.08.001","volume":"116","author":"HY Luo","year":"2025","unstructured":"Luo HY, et al. Microbiome unlocks cancer immunotherapeutic potential: State of the art and future. Semin Cancer Biol. 2025;116:1\u201321.","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"4316_CR7","first-page":"647","volume":"7","author":"CB Zhou","year":"2021","unstructured":"Zhou CB, Zhou YL, Fang JY. Gut Microbiota Cancer Immune Response Immunotherapy Trends Cancer. 2021;7(7):647\u201360.","journal-title":"Gut Microbiota Cancer Immune Response Immunotherapy Trends Cancer"},{"issue":"4","key":"4316_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.gendis.2016.07.003","volume":"3","author":"L Cai","year":"2016","unstructured":"Cai L, et al. CRISPR-mediated genome editing and human diseases. Genes Dis. 2016;3(4):244\u201351.","journal-title":"Genes Dis"},{"issue":"1","key":"4316_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-024-02028-3","volume":"9","author":"C Zhu","year":"2024","unstructured":"Zhu C, et al. Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors. Signal Transduct Target Therapy. 2024;9(1):307.","journal-title":"Signal Transduct Target Therapy"},{"issue":"16","key":"4316_CR10","doi-asserted-by":"publisher","first-page":"e22140","DOI":"10.1002\/adma.202522140","volume":"38","author":"C Zhu","year":"2026","unstructured":"Zhu C, et al. Engineered Bacterial Biomaterials for Augmenting Adoptive Immune Cell Therapy Against Solid Tumors. Adv Mater. 2026;38(16):e22140.","journal-title":"Adv Mater"},{"issue":"9","key":"4316_CR11","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.3390\/jcm14092982","volume":"14","author":"IG Dumitru","year":"2025","unstructured":"Dumitru IG, et al. A Literature Review on the Impact of the Gut Microbiome on Cancer Treatment Efficacy, Disease Evolution and Toxicity: The Implications for Hematological Malignancies. J Clin Med. 2025;14(9):2982.","journal-title":"J Clin Med"},{"issue":"1","key":"4316_CR12","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1038\/s41467-022-32960-3","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu Y, et al. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nat Commun. 2022;13(1):5313.","journal-title":"Nat Commun"},{"key":"4316_CR13","doi-asserted-by":"publisher","first-page":"1512683","DOI":"10.3389\/fimmu.2024.1512683","volume":"15","author":"MY Lim","year":"2024","unstructured":"Lim MY, Hong S, Nam YD. Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review. Front Immunol. 2024;15:1512683.","journal-title":"Front Immunol"},{"key":"4316_CR14","doi-asserted-by":"publisher","first-page":"766275","DOI":"10.3389\/fimmu.2021.766275","volume":"12","author":"SJC Mancini","year":"2021","unstructured":"Mancini SJC, et al. Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies. Front Immunol. 2021;12:766275.","journal-title":"Front Immunol"},{"issue":"1","key":"4316_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40164-024-00570-y","volume":"13","author":"X Feng","year":"2024","unstructured":"Feng X, et al. CRISPR\/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications. Exp Hematol Oncol. 2024;13(1):102.","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"4316_CR16","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.ymthe.2021.10.001","volume":"29","author":"T Murty","year":"2021","unstructured":"Murty T, Mackall CL. Gene editing to enhance the efficacy of cancer cell therapies. Mol Ther. 2021;29(11):3153\u201362.","journal-title":"Mol Ther"},{"key":"4316_CR17","unstructured":"Saksham S, Chauhan, Singh G. WITH CRISPR\/CAS9, FIGHTING AGAINST THE DARK EMPIRE OF DISEASES. 2022. 15: pp. 29\u201333."},{"issue":"2","key":"4316_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11248-020-00232-9","volume":"30","author":"EK Elliott","year":"2021","unstructured":"Elliott EK, Haupt LM, Griffiths LR. Mini review: genome and transcriptome editing using CRISPR-cas systems for haematological malignancy gene therapy. Transgenic Res. 2021;30(2):129\u201341.","journal-title":"Transgenic Res"},{"issue":"1","key":"4316_CR19","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","volume":"12","author":"L Giuffrida","year":"2021","unstructured":"Giuffrida L, et al. CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat Commun. 2021;12(1):3236.","journal-title":"Nat Commun"},{"key":"4316_CR20","unstructured":"Sharma B. Innovative Translation Strategies in the Emergence of Next-Generation Drugs in Precision Cancer Medicine. Journal of Modern Medical Oncology; 2022."},{"issue":"4","key":"4316_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.stem.2019.08.004","volume":"25","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, et al. Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell Stem Cell. 2019;25(4):542\u2013e5579.","journal-title":"Cell Stem Cell"},{"key":"4316_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.21103\/Article12(1)_GE","volume":"12","author":"G Rao","year":"2022","unstructured":"Rao G. Role of Biomolecules and Biologics in Precision Medicine, Personalized Medicine, and Emerging Therapies. Int J Biomed. 2022;12:70\u201381.","journal-title":"Int J Biomed"},{"issue":"8026","key":"4316_CR23","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41586-024-07681-w","volume":"632","author":"AK Br\u00f6del","year":"2024","unstructured":"Br\u00f6del AK, et al. In situ targeted base editing of bacteria in the mouse gut. Nature. 2024;632(8026):877\u201384.","journal-title":"Nature"},{"issue":"1","key":"4316_CR24","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s12602-025-10561-y","volume":"18","author":"R Rahmati","year":"2026","unstructured":"Rahmati R, et al. CRISPR-Assisted Probiotic and In Situ Engineering of Gut Microbiota: A Prospect to Modification of Metabolic Disorders. Probiotics Antimicrob Proteins. 2026;18(1):1570\u201386.","journal-title":"Probiotics Antimicrob Proteins"},{"key":"4316_CR25","doi-asserted-by":"publisher","first-page":"1041451","DOI":"10.3389\/fimmu.2022.1041451","volume":"13","author":"EA Holcomb","year":"2022","unstructured":"Holcomb EA, et al. High-content CRISPR screening in tumor immunology. Front Immunol. 2022;13:1041451.","journal-title":"Front Immunol"},{"issue":"6","key":"4316_CR26","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1158\/1541-7786.MCR-20-0652","volume":"19","author":"X Zhang","year":"2021","unstructured":"Zhang X, et al. Qa-1(b) Modulates Resistance to Anti-PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing. Mol Cancer Res. 2021;19(6):1076\u201384.","journal-title":"Mol Cancer Res"},{"key":"4316_CR27","first-page":"353","volume":"15","author":"M Asmamaw","year":"2021","unstructured":"Asmamaw M, Zawdie B. Mechanism and Applications of CRISPR\/Cas-9-Mediated Genome Editing. Biologics. 2021;15:353\u201361.","journal-title":"Biologics"},{"issue":"5","key":"4316_CR28","first-page":"540","volume":"28","author":"A Joseph","year":"2022","unstructured":"Joseph A, et al. Severe infections in recipients of cancer immunotherapy: what intensivists need to know. Curr Opin Crit Care. 2022;28(5):540\u201350.","journal-title":"Curr Opin Crit Care"},{"issue":"1","key":"4316_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/imm.13793","volume":"173","author":"ZB Wang","year":"2024","unstructured":"Wang ZB, et al. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy. Immunology. 2024;173(1):14\u201332.","journal-title":"Immunology"},{"issue":"1","key":"4316_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cr.2018.08.002","volume":"7","author":"H Cheng","year":"2018","unstructured":"Cheng H, Sun G, Cheng T. Hematopoiesis and microenvironment in hematological malignancies. Cell Regen. 2018;7(1):22\u20136.","journal-title":"Cell Regen"},{"key":"4316_CR31","doi-asserted-by":"publisher","first-page":"1407981","DOI":"10.3389\/fimmu.2024.1407981","volume":"15","author":"S Fiorcari","year":"2024","unstructured":"Fiorcari S, Strati P, Dondi E. Editorial: Tumor microenvironment and hematological malignancies: new evidences and new questions. Front Immunol. 2024;15:1407981.","journal-title":"Front Immunol"},{"issue":"3","key":"4316_CR32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.bbamcr.2015.07.008","volume":"1863","author":"M Yan","year":"2016","unstructured":"Yan M, Jurasz P. The role of platelets in the tumor microenvironment: From solid tumors to leukemia. Biochim Biophys Acta. 2016;1863(3):392\u2013400.","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"4316_CR33","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood-2016-09-670224","volume":"129","author":"C Korn","year":"2017","unstructured":"Korn C, M\u00e9ndez-Ferrer S. Myeloid malignancies and the microenvironment. Blood. 2017;129(7):811\u201322.","journal-title":"Blood"},{"issue":"10","key":"4316_CR34","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.3324\/haematol.2018.195396","volume":"104","author":"D Forte","year":"2019","unstructured":"Forte D, et al. Updates on the hematologic tumor microenvironment and its therapeutic targeting. Haematologica. 2019;104(10):1928\u201334.","journal-title":"Haematologica"},{"issue":"16","key":"4316_CR35","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.21037\/atm-21-3924","volume":"9","author":"P Chen","year":"2021","unstructured":"Chen P, et al. A bibliometric analysis of the research on hematological tumor microenvironment. Ann Transl Med. 2021;9(16):1337.","journal-title":"Ann Transl Med"},{"key":"4316_CR36","doi-asserted-by":"crossref","unstructured":"Das K, Mukherjee T, Shankar P. The Role of Extracellular Vesicles in the Pathogenesis of Hematological Malignancies: Interaction with Tumor Microenvironment; a Potential Biomarker and Targeted Therapy. Biomolecules. 2023;13(6):897.","DOI":"10.3390\/biom13060897"},{"issue":"12","key":"4316_CR37","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1182\/blood-2016-11-696070","volume":"129","author":"H Medyouf","year":"2017","unstructured":"Medyouf H. The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications. Blood. 2017;129(12):1617\u201326.","journal-title":"Blood"},{"issue":"6","key":"4316_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.trecan.2019.05.001","volume":"5","author":"UE H\u00f6pken","year":"2019","unstructured":"H\u00f6pken UE, Rehm A. Targeting the Tumor Microenvironment of Leukemia and Lymphoma. Trends Cancer. 2019;5(6):351\u201364.","journal-title":"Trends Cancer"},{"key":"4316_CR39","doi-asserted-by":"crossref","unstructured":"Hassan G, Seno M. Blood and Cancer: Cancer Stem Cells as Origin of Hematopoietic Cells in Solid Tumor Microenvironments. Cells, 2020. 9(5).p.1293","DOI":"10.3390\/cells9051293"},{"issue":"5","key":"4316_CR40","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3324\/haematol.2015.139493","volume":"101","author":"NH Fowler","year":"2016","unstructured":"Fowler NH, et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 2016;101(5):531\u201340.","journal-title":"Haematologica"},{"key":"4316_CR41","doi-asserted-by":"crossref","unstructured":"Cencini E, et al. The Role of Tumor-Associated Macrophages in Hematologic Malignancies. Cancers (Basel). 2021;13(14):3597.","DOI":"10.3390\/cancers13143597"},{"issue":"3","key":"4316_CR42","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.bbamcr.2015.11.003","volume":"1863","author":"NS Nicholas","year":"2016","unstructured":"Nicholas NS, Apollonio B, Ramsay AG. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. Biochim Biophys Acta. 2016;1863(3):471\u201382.","journal-title":"Biochim Biophys Acta"},{"key":"4316_CR43","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ortiz A, et al. The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers (Basel). 2021;13(2):217.","DOI":"10.3390\/cancers13020217"},{"key":"4316_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fonc.2020.00230","volume":"10","author":"C Hellmich","year":"2020","unstructured":"Hellmich C, et al. Bone Marrow Senescence and the Microenvironment of Hematological Malignancies. Front Oncol. 2020;10:230.","journal-title":"Front Oncol"},{"key":"4316_CR45","doi-asserted-by":"publisher","first-page":"811144","DOI":"10.3389\/fimmu.2022.811144","volume":"13","author":"T Menter","year":"2022","unstructured":"Menter T, Tzankov A. Tumor Microenvironment in Acute Myeloid Leukemia: Adjusting Niches. Front Immunol. 2022;13:811144.","journal-title":"Front Immunol"},{"issue":"5","key":"4316_CR46","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/cncr.33400","volume":"127","author":"CR D\u2019Angelo","year":"2021","unstructured":"D\u2019Angelo CR, Sudakaran S, Callander NS. Clinical effects and applications of the gut microbiome in hematologic malignancies. Cancer. 2021;127(5):679\u201387.","journal-title":"Cancer"},{"issue":"8","key":"4316_CR47","doi-asserted-by":"publisher","first-page":"e14193","DOI":"10.1111\/apha.14193","volume":"240","author":"E Dinakis","year":"2024","unstructured":"Dinakis E, O\u2019Donnell JA, Marques FZ. The gut-immune axis during hypertension and cardiovascular diseases. Acta Physiol (Oxf). 2024;240(8):e14193.","journal-title":"Acta Physiol (Oxf)"},{"issue":"12","key":"4316_CR48","doi-asserted-by":"publisher","first-page":"e32831","DOI":"10.1016\/j.heliyon.2024.e32831","volume":"10","author":"C Wells","year":"2024","unstructured":"Wells C, et al. How aging influences the gut-bone marrow axis and alters hematopoietic stem cell regulation. Heliyon. 2024;10(12):e32831.","journal-title":"Heliyon"},{"issue":"2","key":"4316_CR49","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.stem.2021.12.009","volume":"29","author":"D Zhang","year":"2022","unstructured":"Zhang D, et al. The microbiota regulates hematopoietic stem cell fate decisions by controlling iron availability in bone marrow. Cell Stem Cell. 2022;29(2):232\u2013e2477.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"4316_CR50","doi-asserted-by":"publisher","first-page":"2350784","DOI":"10.1080\/19490976.2024.2350784","volume":"16","author":"K Zheng","year":"2024","unstructured":"Zheng K, Wei Z, Li W. Ecological insights into hematopoiesis regulation: unraveling the influence of gut microbiota. Gut Microbes. 2024;16(1):2350784.","journal-title":"Gut Microbes"},{"key":"4316_CR51","doi-asserted-by":"publisher","first-page":"103289","DOI":"10.1016\/j.critrevonc.2021.103289","volume":"160","author":"B Fattizzo","year":"2021","unstructured":"Fattizzo B, et al. Recent insights into the role of the microbiome in malignant and benign hematologic diseases. Crit Rev Oncol Hematol. 2021;160:103289.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"4316_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1158\/1541-7786.MCR-23-0080","volume":"22","author":"N Hussein","year":"2024","unstructured":"Hussein N, et al. The Role of the Gut Microbiome in Hematological Cancers. Mol Cancer Res. 2024;22(1):7\u201320.","journal-title":"Mol Cancer Res"},{"issue":"8","key":"4316_CR53","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.tim.2025.03.011","volume":"33","author":"YR Li","year":"2025","unstructured":"Li YR, et al. The microbiota shapes the life trajectory of mucosal-associated invariant T cells. Trends Microbiol. 2025;33(8):903\u201319.","journal-title":"Trends Microbiol"},{"issue":"611","key":"4316_CR54","first-page":"pe70445","volume":"2025","author":"C Zhu","year":"2020","unstructured":"Zhu C, et al. Mucosal-Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets. MedComm. 2020;2025(611):pe70445.","journal-title":"MedComm"},{"key":"4316_CR55","doi-asserted-by":"crossref","unstructured":"Akhremchuk A et al. Gut microbiome of healthy people and patients with hematological malignancies in Belarus. Microbiol Indep Res J (MIR Journal), 2022. 9.","DOI":"10.18527\/2500-2236-2022-9-1-18-30"},{"key":"4316_CR56","doi-asserted-by":"crossref","unstructured":"Zhu Y, et al. Intestinal Microbes and Hematological Malignancies. Cancers (Basel). 2023;15(8):2284.","DOI":"10.3390\/cancers15082284"},{"key":"4316_CR57","doi-asserted-by":"publisher","first-page":"1185787","DOI":"10.3389\/fmicb.2023.1185787","volume":"14","author":"P Guevara-Ram\u00edrez","year":"2023","unstructured":"Guevara-Ram\u00edrez P, et al. Role of the gut microbiota in hematologic cancer. Front Microbiol. 2023;14:1185787.","journal-title":"Front Microbiol"},{"key":"4316_CR58","doi-asserted-by":"crossref","unstructured":"Uribe-Herranz M et al. Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure. Int J Mol Sci, 2021;22(3):1026.","DOI":"10.3390\/ijms22031026"},{"key":"4316_CR59","doi-asserted-by":"publisher","first-page":"1412035","DOI":"10.3389\/fcimb.2024.1412035","volume":"14","author":"P Chen","year":"2024","unstructured":"Chen P, et al. Refining the relationship between gut microbiota and common hematologic malignancies: insights from a bidirectional Mendelian randomization study. Front Cell Infect Microbiol. 2024;14:1412035.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"4316_CR60","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1186\/s12885-021-08296-4","volume":"21","author":"LE Papanicolas","year":"2021","unstructured":"Papanicolas LE, et al. Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome. BMC Cancer. 2021;21(1):591.","journal-title":"BMC Cancer"},{"key":"4316_CR61","doi-asserted-by":"crossref","unstructured":"Mougeot JC, et al. Oral Microbiome Signatures in Hematological Cancers Reveal Predominance of Actinomyces and Rothia Species. J Clin Med. 2020;9(12):4068.","DOI":"10.3390\/jcm9124068"},{"issue":"2","key":"4316_CR62","first-page":"67","volume":"77","author":"A Allegra","year":"2019","unstructured":"Allegra A, et al. Role of the microbiota in hematologic malignancies. Neth J Med. 2019;77(2):67\u201380.","journal-title":"Neth J Med"},{"issue":"9","key":"4316_CR63","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3324\/haematol.2021.280455","volume":"107","author":"T Faitov\u00e1","year":"2022","unstructured":"Faitov\u00e1 T, et al. The gut microbiome in patients with chronic lymphocytic leukemia. Haematologica. 2022;107(9):2238\u201343.","journal-title":"Haematologica"},{"issue":"5","key":"4316_CR64","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.7150\/ijbs.92988","volume":"20","author":"WX Xu","year":"2024","unstructured":"Xu WX, et al. The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers. Int J Biol Sci. 2024;20(5):1652\u201368.","journal-title":"Int J Biol Sci"},{"issue":"7","key":"4316_CR65","doi-asserted-by":"publisher","first-page":"ofz252","DOI":"10.1093\/ofid\/ofz252","volume":"6","author":"M Ziegler","year":"2019","unstructured":"Ziegler M, et al. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients With Hematologic Malignancy. Open Forum Infect Dis. 2019;6(7):ofz252.","journal-title":"Open Forum Infect Dis"},{"key":"4316_CR66","doi-asserted-by":"crossref","unstructured":"D\u2019Amico F et al. Oral Lactoferrin Supplementation during Induction Chemotherapy Promotes Gut Microbiome Eubiosis in Pediatric Patients with Hematologic Malignancies. Pharmaceutics, 2022;14(8):1705 [online]","DOI":"10.3390\/pharmaceutics14081705"},{"issue":"2","key":"4316_CR67","doi-asserted-by":"publisher","first-page":"103320","DOI":"10.1016\/j.transci.2021.103320","volume":"61","author":"R Ciftciler","year":"2022","unstructured":"Ciftciler R, Ciftciler AE. The importance of microbiota in hematology. Transfus Apher Sci. 2022;61(2):103320.","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"4316_CR68","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2015-04-574392","volume":"126","author":"VE Manzo","year":"2015","unstructured":"Manzo VE, Bhatt AS. The human microbiome in hematopoiesis and hematologic disorders. Blood. 2015;126(3):311\u20138.","journal-title":"Blood"},{"issue":"3","key":"4316_CR69","doi-asserted-by":"publisher","first-page":"e70501","DOI":"10.1002\/cam4.70501","volume":"14","author":"V Salvestrini","year":"2025","unstructured":"Salvestrini V, et al. Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients. Cancer Med. 2025;14(3):e70501.","journal-title":"Cancer Med"},{"key":"4316_CR70","doi-asserted-by":"crossref","unstructured":"Guevara-Ram\u00edrez P, et al. Gut Microbiota Disruption in Hematologic Cancer Therapy: Molecular Insights and Implications for Treatment Efficacy. Int J Mol Sci. 2024;25(19):10255.","DOI":"10.3390\/ijms251910255"},{"key":"4316_CR71","doi-asserted-by":"crossref","unstructured":"Ternak G et al. Possible Role of the Antibiotic-Modified Microbiome in the Development of Hematological Malignancies in European Countries. 2022.","DOI":"10.20944\/preprints202201.0162.v1"},{"key":"4316_CR72","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcdb.2019.05.026","volume":"96","author":"Z Mirza","year":"2019","unstructured":"Mirza Z, Karim S. Advancements in CRISPR\/Cas9 technology-Focusing on cancer therapeutics and beyond. Semin Cell Dev Biol. 2019;96:13\u201321.","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"4316_CR73","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12967-022-03765-1","volume":"20","author":"AA Bhat","year":"2022","unstructured":"Bhat AA, et al. Integration of CRISPR\/Cas9 with artificial intelligence for improved cancer therapeutics. J Transl Med. 2022;20(1):534.","journal-title":"J Transl Med"},{"key":"4316_CR74","doi-asserted-by":"crossref","unstructured":"Stefanoudakis D et al. The Potential Revolution of Cancer Treatment with CRISPR Technology. Cancers (Basel), 2023. 15(6).1813 [online]","DOI":"10.3390\/cancers15061813"},{"issue":"5","key":"4316_CR75","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41568-022-00441-w","volume":"22","author":"A Katti","year":"2022","unstructured":"Katti A, et al. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022;22(5):259\u201379.","journal-title":"Nat Rev Cancer"},{"key":"4316_CR76","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12935-019-0726-0","volume":"19","author":"D Ghosh","year":"2019","unstructured":"Ghosh D, et al. CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Cancer Cell Int. 2019;19:12.","journal-title":"Cancer Cell Int"},{"key":"4316_CR77","doi-asserted-by":"crossref","unstructured":"Mintz RL, et al. CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy. Adv Biosyst. 2018;2(11):1800132.","DOI":"10.1002\/adbi.201800132"},{"issue":"9","key":"4316_CR78","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s44222-023-00072-2","volume":"1","author":"X Bai","year":"2023","unstructured":"Bai X, et al. Engineering the gut microbiome. Nat Reviews Bioeng. 2023;1(9):665\u201379.","journal-title":"Nat Reviews Bioeng"},{"issue":"11","key":"4316_CR79","doi-asserted-by":"publisher","first-page":"e2304378","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, et al. Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism. Small. 2024;20(11):e2304378.","journal-title":"Small"},{"issue":"11","key":"4316_CR80","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","volume":"42","author":"JR Hamilton","year":"2024","unstructured":"Hamilton JR, et al. In vivo human T cell engineering with enveloped delivery vehicles. Nat Biotechnol. 2024;42(11):1684\u201392.","journal-title":"Nat Biotechnol"},{"key":"4316_CR81","unstructured":"Nyberg WA et al. In vivo site-specific engineering to reprogram T cells. Nature, 2026. pp.1\u201310."},{"issue":"1","key":"4316_CR82","doi-asserted-by":"publisher","first-page":"10218","DOI":"10.1038\/s41467-024-54292-0","volume":"15","author":"J Qu","year":"2024","unstructured":"Qu J, et al. In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy. Nat Commun. 2024;15(1):10218.","journal-title":"Nat Commun"},{"issue":"6576","key":"4316_CR83","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91\u20136.","journal-title":"Science"},{"issue":"5","key":"4316_CR84","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.7150\/ijbs.92988","volume":"20","author":"WX Xu","year":"2024","unstructured":"Xu WX, Qu Q, Zhuang HH, Teng XQ, Wei YW, Luo J, Dai YH, Qu J. The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers. Int J Biol Sci. 2024;20(5):1652\u201368.","journal-title":"Int J Biol Sci"},{"issue":"1772","key":"4316_CR85","doi-asserted-by":"publisher","first-page":"20180103","DOI":"10.1098\/rstb.2018.0103","volume":"374","author":"G Ramachandran","year":"2019","unstructured":"Ramachandran G, Bikard D. Editing the microbiome the CRISPR way. Philos Trans R Soc Lond B Biol Sci. 2019;374(1772):20180103.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"4316_CR86","doi-asserted-by":"publisher","first-page":"103020","DOI":"10.1016\/j.mtbio.2026.103020","volume":"37","author":"J Yu","year":"2026","unstructured":"Yu J, et al. Endogenous living adjuvants for cancer vaccination: Concepts, mechanisms, and design principles. Mater Today Bio. 2026;37:103020.","journal-title":"Mater Today Bio"},{"key":"4316_CR87","doi-asserted-by":"crossref","unstructured":"Jafarabadi M, Khaledi A. Escherichia coli bloodstream infections and associated antibiotic resistance pattern in hematological malignancy populations, a global systematic review. Eurasian J Med Oncol. 2024;8(1):15\u201323.","DOI":"10.14744\/ejmo.2024.79645"},{"issue":"1","key":"4316_CR88","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.chom.2020.10.010","volume":"29","author":"PC M\u00fcnch","year":"2021","unstructured":"M\u00fcnch PC, et al. Identification of Natural CRISPR Systems and Targets in the Human Microbiome. Cell Host Microbe. 2021;29(1):94\u2013e1064.","journal-title":"Cell Host Microbe"},{"key":"4316_CR89","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.mib.2019.09.005","volume":"50","author":"T Whitfill","year":"2019","unstructured":"Whitfill T, Oh J. Recoding the metagenome: microbiome engineering in situ. Curr Opin Microbiol. 2019;50:28\u201334.","journal-title":"Curr Opin Microbiol"},{"key":"4316_CR90","first-page":"865","volume":"9","author":"G Berhanu","year":"2021","unstructured":"Berhanu G, Godishala V, Kandi V. Microbiome Engineering and Its Applications: A Rapid Review. Appl Ecol Environ Sci. 2021;9:865\u201372.","journal-title":"Appl Ecol Environ Sci"},{"issue":"10","key":"4316_CR91","doi-asserted-by":"publisher","first-page":"MSB202110335","DOI":"10.15252\/msb.202110335","volume":"17","author":"K Neil","year":"2021","unstructured":"Neil K, et al. High-efficiency delivery of CRISPR\u2010Cas9 by engineered probiotics enables precise microbiome editing. Mol Syst Biol. 2021;17(10):MSB202110335.","journal-title":"Mol Syst Biol"},{"issue":"10","key":"4316_CR92","first-page":"952","volume":"40","author":"ME Inda","year":"2019","unstructured":"Inda ME, et al. Emerging Front Microbiome Eng Trends Immunol. 2019;40(10):952\u201373.","journal-title":"Emerging Front Microbiome Eng Trends Immunol"},{"issue":"7","key":"4316_CR93","first-page":"e0012723","volume":"205","author":"J Arnold","year":"2023","unstructured":"Arnold J, Glazier J, Mimee M. Genetic Eng Resident Bacteria Gut Microbiome J Bacteriol. 2023;205(7):e0012723.","journal-title":"Genetic Eng Resident Bacteria Gut Microbiome J Bacteriol"},{"key":"4316_CR94","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","volume":"11","author":"TA Waldmann","year":"2020","unstructured":"Waldmann TA, et al. IL-15 in the Combination Immunotherapy of Cancer. Front Immunol. 2020;11:868.","journal-title":"Front Immunol"},{"key":"4316_CR95","doi-asserted-by":"publisher","first-page":"1141208","DOI":"10.3389\/fimmu.2023.1141208","volume":"14","author":"P Sindaco","year":"2023","unstructured":"Sindaco P, et al. The role of interleukin-15 in the development and treatment of hematological malignancies. Front Immunol. 2023;14:1141208.","journal-title":"Front Immunol"},{"key":"4316_CR96","doi-asserted-by":"crossref","unstructured":"Rautela J, Huntington ND. IL-15 signaling in NK cell cancer immunotherapy. Curr Opin Immunol, 2017. 44: pp. 1\u20136.","DOI":"10.1016\/j.coi.2016.10.004"},{"key":"4316_CR97","doi-asserted-by":"crossref","unstructured":"Bergamaschi C et al. Heterodimeric IL-15 in Cancer Immunotherapy. Cancers (Basel), 2021. 13(4).","DOI":"10.3390\/cancers13040837"},{"issue":"7","key":"4316_CR98","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/14712598.2020.1738379","volume":"20","author":"KM Knudson","year":"2020","unstructured":"Knudson KM, et al. Rationale for IL-15 superagonists in cancer immunotherapy. Expert Opin Biol Ther. 2020;20(7):705\u20139.","journal-title":"Expert Opin Biol Ther"},{"issue":"20","key":"4316_CR99","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2174\/0118715206321574240821112747","volume":"24","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. Immunomodulatory Roles of IL-15 in Immune Cells and its Potential for Cancer Immunotherapy. Anticancer Agents Med Chem. 2024;24(20):1457\u201366.","journal-title":"Anticancer Agents Med Chem"},{"issue":"10","key":"4316_CR100","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","volume":"43","author":"S Ma","year":"2022","unstructured":"Ma S, Caligiuri MA, Yu J. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends Immunol. 2022;43(10):833\u201347.","journal-title":"Trends Immunol"},{"key":"4316_CR101","doi-asserted-by":"crossref","unstructured":"Yang Y, Lundqvist A. Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy. Cancers (Basel), 2020. 12(12).2020 [online].","DOI":"10.3390\/cancers12123586"},{"key":"4316_CR102","doi-asserted-by":"crossref","unstructured":"Fiore PF, et al. Interleukin-15 and cancer: some solved and many unsolved questions. J Immunother Cancer. 2020;8(2):e001428.","DOI":"10.1136\/jitc-2020-001428"},{"issue":"24","key":"4316_CR103","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/0008-5472.CAN-15-1498","volume":"75","author":"K Pilipow","year":"2015","unstructured":"Pilipow K, et al. IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. Cancer Res. 2015;75(24):5187\u201393.","journal-title":"Cancer Res"},{"issue":"13","key":"4316_CR104","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.3390\/ijms23137311","volume":"23","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Husman T, Cen X, Tsao T, Brown J, Bajpai A, Yang L. Interleukin 15 in cell-based cancer immunotherapy. Int J Mol Sci. 2022;23(13):7311.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4316_CR105","doi-asserted-by":"publisher","first-page":"e004104","DOI":"10.1136\/jitc-2021-004104","volume":"10","author":"JA Hangasky","year":"2022","unstructured":"Hangasky JA, Chen W, Dubois SP, Daenthanasanmak A, M\u00fcller JR, Reid R, Santi DV. A very long-acting IL-15: implications for the immunotherapy of cancer. J Immunother Cancer. 2022;10(1):e004104.","journal-title":"J Immunother Cancer"},{"key":"4316_CR106","doi-asserted-by":"publisher","first-page":"1184703","DOI":"10.3389\/fphar.2023.1184703","volume":"14","author":"M Cai","year":"2023","unstructured":"Cai M, Huang X, Huang X, Ju D, Zhu YZ, Ye L. Research progress of interleukin-15 in cancer immunotherapy. Front Pharmacol. 2023;14:1184703.","journal-title":"Front Pharmacol"},{"issue":"9","key":"4316_CR107","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1021\/acsbiomaterials.2c00202","volume":"9","author":"KJ Chua","year":"2022","unstructured":"Chua KJ, Ling H, Hwang IY, Lee HL, March JC, Lee YS, Chang MW. An engineered probiotic produces a type III interferon IFNL1 and reduces inflammations in in vitro inflammatory bowel disease models. ACS Biomaterials Sci Eng. 2022;9(9):5123\u201335.","journal-title":"ACS Biomaterials Sci Eng"},{"issue":"11","key":"4316_CR108","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41551-021-00749-2","volume":"5","author":"K Han","year":"2021","unstructured":"Han K, Nam J, Xu J, Sun X, Huang X, Animasahun O, Moon JJ. Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel. Nat biomedical Eng. 2021;5(11):1377\u201388.","journal-title":"Nat biomedical Eng"},{"key":"4316_CR109","doi-asserted-by":"publisher","first-page":"629141","DOI":"10.3389\/fphys.2020.629141","volume":"11","author":"R Yue","year":"2021","unstructured":"Yue R, Wei X, Zhao J, Zhou Z, Zhong W. Essential role of IFN-\u03b3 in regulating gut antimicrobial peptides and microbiota to protect against alcohol-induced bacterial translocation and hepatic inflammation in mice. Front Physiol. 2021;11:629141.","journal-title":"Front Physiol"},{"key":"4316_CR110","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2016.10.010","volume":"70","author":"W Yoon","year":"2017","unstructured":"Yoon W, Park YC, Kim J, Chae YS, Byeon JH, Min SH, Kim BM. Application of genetically engineered Salmonella typhimurium for interferon-gamma\u2013induced therapy against melanoma. Eur J Cancer. 2017;70:48\u201361.","journal-title":"Eur J Cancer"},{"issue":"8","key":"4316_CR111","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1016\/j.ymthe.2024.06.017","volume":"32","author":"L Ma","year":"2024","unstructured":"Ma L, Zhang K, Xu J, Wang J, Jiang T, Du X, Jason-Sun H. Building a novel TRUCK by harnessing the endogenous IFN-gamma promoter for cytokine expression. Mol Ther. 2024;32(8):2728\u201340.","journal-title":"Mol Ther"},{"issue":"3","key":"4316_CR112","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mBio.00366-21","volume":"12","author":"XL Yang","year":"2021","unstructured":"Yang XL, Wang G, Xie JY, Li H, Chen SX, Liu W, Zhu SJ. The intestinal microbiome primes host innate immunity against enteric virus systemic infection through type I interferon. MBio. 2021;12(3):10\u20131128.","journal-title":"MBio"},{"issue":"7989","key":"4316_CR113","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41586-023-06721-1","volume":"623","author":"A Malik","year":"2023","unstructured":"Malik A, Sharma D, Aguirre-Gamboa R, McGrath S, Zabala S, Weber C, Jabri B. Epithelial IFN\u03b3 signalling and compartmentalized antigen presentation orchestrate gut immunity. Nature. 2023;623(7989):1044\u201352.","journal-title":"Nature"},{"issue":"21","key":"4316_CR114","first-page":"5338","volume":"184","author":"KC Lam","year":"2021","unstructured":"Lam KC, Araya RE, Huang A, Chen Q, Di Modica M, Rodrigues RR, Goldszmid RS. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell Death Dis. 2021;184(21):5338\u201356.","journal-title":"Cell Death Dis"},{"key":"4316_CR115","doi-asserted-by":"crossref","unstructured":"Fu Y, Duan B, Zheng P, Chu H, Li W, Yang Y, Ma Y. Genetically modified bacterial vesicles with interferon-\u03b3 and tumor antigen remodel anti-tumor cellular immunity by modulating dendritic cells. Biomaterials, 2025;324:123524.","DOI":"10.1016\/j.biomaterials.2025.123524"},{"key":"4316_CR116","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1073\/pnas.1000082107","volume":"108","author":"YK Lee","year":"2011","unstructured":"Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci. 2011;108:4615\u201322.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"4316_CR117","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s43440-023-00454-8","volume":"75","author":"A Kiecka","year":"2023","unstructured":"Kiecka A, Macura B, Szczepanik M. Modulation of allergic contact dermatitis via gut microbiota modified by diet, vitamins, probiotics, prebiotics, and antibiotics. Pharmacol Rep. 2023;75(2):236\u201348.","journal-title":"Pharmacol Rep"},{"issue":"10","key":"4316_CR118","doi-asserted-by":"publisher","first-page":"2003542","DOI":"10.1002\/advs.202003542","volume":"8","author":"R Zhu","year":"2021","unstructured":"Zhu R, Lang T, Yan W, Zhu X, Huang X, Yin Q, Li Y. Gut microbiota: influence on carcinogenesis and modulation strategies by drug delivery systems to improve cancer therapy. Adv Sci. 2021;8(10):2003542.","journal-title":"Adv Sci"},{"issue":"5","key":"4316_CR119","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1007\/s11427-022-2229-1","volume":"66","author":"W Huang","year":"2023","unstructured":"Huang W, Ma T, Liu Y, Kwok LY, Li Y, Jin H, Zhang H. Spraying compound probiotics improves growth performance and immunity and modulates gut microbiota and blood metabolites of suckling piglets. Sci China life Sci. 2023;66(5):1092\u2013107.","journal-title":"Sci China life Sci"},{"issue":"6","key":"4316_CR120","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1080\/09540105.2017.1346063","volume":"28","author":"N Zhang","year":"2017","unstructured":"Zhang N, Hou E, Song J, Li J, Tang Q, Mao X. Neoagarotetraose-modulated gut microbiota and alleviated gut inflammation in antibiotic treatment mice. Food Agricultural Immunol. 2017;28(6):1408\u201323.","journal-title":"Food Agricultural Immunol"},{"issue":"7","key":"4316_CR121","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1038\/s44319-025-00386-9","volume":"26","author":"TH Vaaben","year":"2025","unstructured":"Vaaben TH, L\u00fctzh\u00f8ft DO, Koulouktsis A, Dawoodi IM, Stavnsbjerg C, Kvich L, Sommer MOA. Modulating tumor immunity using advanced microbiome therapeutics producing an indole metabolite. EMBO Rep. 2025;26(7):1688\u2013708.","journal-title":"EMBO Rep"},{"key":"4316_CR122","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3389\/fphar.2020.01249","volume":"11","author":"TT Cai","year":"2020","unstructured":"Cai TT, Ye XL, Li RR, Chen H, Wang YY, Yong HJ, Ding DF. Resveratrol modulates the gut microbiota and inflammation to protect against diabetic nephropathy in mice. Front Pharmacol. 2020;11:1249.","journal-title":"Front Pharmacol"},{"key":"4316_CR123","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.2147\/JIR.S499403","volume":"18","author":"S Zhang","year":"2025","unstructured":"Zhang S, et al. The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy. J Inflamm Res. 2025;18:4335\u201357.","journal-title":"J Inflamm Res"},{"key":"4316_CR124","doi-asserted-by":"publisher","first-page":"102186","DOI":"10.1016\/j.nantod.2024.102186","volume":"55","author":"X Zhao","year":"2024","unstructured":"Zhao X, Guo K, Zhang K, Ding X, Zhao N, Xu FJ. Degradable CRISPR\/Cas9 nanosystem activated by NIR-II light targets genome editing of PD-L1 and metabolic modulation for enhanced antitumor immunity. Nano Today. 2024;55:102186.","journal-title":"Nano Today"},{"key":"4316_CR125","doi-asserted-by":"publisher","first-page":"848327","DOI":"10.3389\/fimmu.2022.848327","volume":"13","author":"Y Xu","year":"2022","unstructured":"Xu Y, Chen C, Guo Y, Hu S, Sun Z. Effect of CRISPR\/Cas9-edited PD-1\/PD-L1 on tumor immunity and immunotherapy. Front Immunol. 2022;13:848327.","journal-title":"Front Immunol"},{"issue":"40","key":"4316_CR126","doi-asserted-by":"publisher","first-page":"402002","DOI":"10.1088\/1361-6528\/ad5f33","volume":"35","author":"LW Tong","year":"2024","unstructured":"Tong LW, Hu YS, Yu SJ, Li CL, Shao JW. Current application and future perspective of CRISPR\/cas9 gene editing system mediated immune checkpoint for liver cancer treatment. Nanotechnology. 2024;35(40):402002.","journal-title":"Nanotechnology"},{"issue":"5","key":"4316_CR127","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1021\/acs.bioconjchem.5c00001","volume":"36","author":"J Zhao","year":"2025","unstructured":"Zhao J, Wang X, Zhang H, Zhang Q, Bo D, Zhong H, Lu G. Tumor Cell Membrane Biomimetic Mesoporous Silicon Materials in Combination with PD-L1 Knockout Achieved through the CRISPR\/Cas9 System for Targeted and Immunotherapeutic Purposes. Bioconjug Chem. 2025;36(5):971\u20139.","journal-title":"Bioconjug Chem"},{"key":"4316_CR128","doi-asserted-by":"publisher","first-page":"119359","DOI":"10.1016\/j.biomaterials.2019.119359","volume":"218","author":"J Lee","year":"2019","unstructured":"Lee J, Le QV, Yang G, Oh YK. Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy. Biomaterials. 2019;218:119359.","journal-title":"Biomaterials"},{"issue":"1","key":"4316_CR129","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12967-023-04014-9","volume":"2","author":"Z Yang","year":"2023","unstructured":"Yang Z, Pietrobon V, Bobbin M, Stefanson O, Yang J, Goswami A, Marincola FM. Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment. J Translational Med. 2023;2(1):158.","journal-title":"J Translational Med"},{"issue":"3","key":"4316_CR130","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.tibtech.2021.08.002","volume":"40","author":"MK Heavey","year":"2022","unstructured":"Heavey MK, et al. Discovery and delivery strategies for engineered live biotherapeutic products. Trends Biotechnol. 2022;40(3):354\u201369.","journal-title":"Trends Biotechnol"},{"issue":"4","key":"4316_CR131","first-page":"643","volume":"10","author":"AC Ouwehand","year":"2003","unstructured":"Ouwehand AC, et al. Disease-dependent adhesion of lactic acid bacteria to the human intestinal mucosa. Clin Diagn Lab Immunol. 2003;10(4):643\u20136.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"1","key":"4316_CR132","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41467-024-44776-4","volume":"15","author":"CR Gurbatri","year":"2024","unstructured":"Gurbatri CR, et al. Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia. Nat Commun. 2024;15(1):646.","journal-title":"Nat Commun"},{"issue":"9","key":"4316_CR133","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.tips.2022.02.002","volume":"43","author":"JP Lynch","year":"2022","unstructured":"Lynch JP, Goers L, Lesser CF. Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics. Trends Pharmacol Sci. 2022;43(9):772\u201386.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"4316_CR134","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.chom.2023.03.007","volume":"31","author":"JP Lynch","year":"2023","unstructured":"Lynch JP, et al. Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut. Cell Host Microbe. 2023;31(4):634\u2013e6498.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"4316_CR135","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1128\/AEM.65.1.351-354.1999","volume":"65","author":"M Alander","year":"1999","unstructured":"Alander M, et al. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol. 1999;65(1):351\u20134.","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"4316_CR136","doi-asserted-by":"publisher","first-page":"e14335","DOI":"10.1111\/1751-7915.14335","volume":"17","author":"M Blanch-Asensio","year":"2024","unstructured":"Blanch-Asensio M, et al. Expanding the genetic programmability of Lactiplantibacillus plantarum. Microb Biotechnol. 2024;17(1):e14335.","journal-title":"Microb Biotechnol"},{"key":"4316_CR137","doi-asserted-by":"crossref","unstructured":"Lin X, et al. Safety Assessment and Probiotic Potential of a Novel Species Lactobacillus xujianguonis. Nutrients. 2025;17(21):3474.","DOI":"10.3390\/nu17213474"},{"issue":"20","key":"4316_CR138","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.7150\/jca.32650","volume":"10","author":"Z Mi","year":"2019","unstructured":"Mi Z, et al. Salmonella-Mediated Cancer Therapy: An Innovative Therapeutic Strategy. J Cancer. 2019;10(20):4765\u201376.","journal-title":"J Cancer"},{"issue":"6","key":"4316_CR139","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/1040841X.2024.2311653","volume":"50","author":"AM Mowday","year":"2024","unstructured":"Mowday AM, et al. Tumor-targeting bacteria as immune stimulants - the future of cancer immunotherapy? Crit Rev Microbiol. 2024;50(6):955\u201370.","journal-title":"Crit Rev Microbiol"},{"key":"4316_CR140","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semcancer.2024.03.003","volume":"100","author":"V Staedtke","year":"2024","unstructured":"Staedtke V, Sun N, Bai R. Hypoxia-targeting bacteria in cancer therapy. Semin Cancer Biol. 2024;100:39\u201348.","journal-title":"Semin Cancer Biol"},{"key":"4316_CR141","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.copbio.2020.11.012","volume":"68","author":"C Fage","year":"2021","unstructured":"Fage C, Lemire N, Moineau S. Delivery of CRISPR-Cas systems using phage-based vectors. Curr Opin Biotechnol. 2021;68:174\u201380.","journal-title":"Curr Opin Biotechnol"},{"issue":"22","key":"4316_CR142","doi-asserted-by":"publisher","first-page":"14245","DOI":"10.3390\/ijms232214245","volume":"23","author":"G Petrov","year":"2022","unstructured":"Petrov G, Dymova M, Richter V. Bacteriophage-mediated cancer gene therapy. Int J Mol Sci. 2022;23(22):14245.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"4316_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0297-0","volume":"51","author":"MT Duong","year":"2019","unstructured":"Duong MT, et al. Bacteria-cancer interactions: bacteria-based cancer therapy. Exp Mol Med. 2019;51(12):1\u201315.","journal-title":"Exp Mol Med"},{"issue":"5","key":"4316_CR144","doi-asserted-by":"publisher","first-page":"109930","DOI":"10.1016\/j.celrep.2021.109930","volume":"37","author":"KN Lam","year":"2021","unstructured":"Lam KN, et al. Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. Cell Rep. 2021;37(5):109930.","journal-title":"Cell Rep"},{"issue":"1","key":"4316_CR145","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13036-021-00269-2","volume":"15","author":"M Samadi","year":"2021","unstructured":"Samadi M, et al. Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo. J Biol Eng. 2021;15(1):20.","journal-title":"J Biol Eng"},{"key":"4316_CR146","doi-asserted-by":"crossref","unstructured":"Shen, J., Lai, Y., Peng, Q., Lin, X., Chen, S., Guo, L., \u2026 Liu, H., Mitochondrial Transplantation: A Paradigm Shift in Osteoporosis Therapy. International Journal of Nanomedicine, 2025: pp. 11169\u201311196.","DOI":"10.2147\/IJN.S537166"},{"key":"4316_CR147","doi-asserted-by":"publisher","first-page":"1111991","DOI":"10.3389\/fphar.2023.1111991","volume":"14","author":"D Chen","year":"2023","unstructured":"Chen D, Liu X, Lu X, Tian J. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. Front Pharmacol. 2023;14:1111991.","journal-title":"Front Pharmacol"},{"key":"4316_CR148","doi-asserted-by":"publisher","first-page":"113664","DOI":"10.1016\/j.jconrel.2025.113664","volume":"382","author":"J Yang","year":"2025","unstructured":"Yang J, et al. Transdermal psoriasis treatment inspired by tumor microenvironment-mediated immunomodulation and advanced by exosomal engineering. J Control Release. 2025;382:113664.","journal-title":"J Control Release"},{"issue":"1","key":"4316_CR149","first-page":"20240248","volume":"6","author":"H Zhang","year":"2026","unstructured":"Zhang H, et al. Surface Charge-Determined Protein Coronas of Nanoparticles Control Endothelial Cells Uptake Under Low Magnitude Shear Stress. Explor (Beijing). 2026;6(1):20240248.","journal-title":"Explor (Beijing)"},{"issue":"2","key":"4316_CR150","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1515\/mr-2022-0047","volume":"3","author":"YN Fan","year":"2023","unstructured":"Fan YN, Zhao G, Zhang Y, Ye QN, Sun YQ, Shen S, Wang J. Progress in nanoparticle-based regulation of immune cells. Med Rev. 2023;3(2):152\u201379.","journal-title":"Med Rev"},{"issue":"3","key":"4316_CR151","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/gt.2016.72","volume":"24","author":"MGZXQ Wang","year":"2017","unstructured":"Wang MGZXQ, Glass ZA, Xu Q. Non-viral delivery of genome-editing nucleases for gene therapy. Gene Ther. 2017;24(3):144\u201350.","journal-title":"Gene Ther"},{"key":"4316_CR152","first-page":"44","volume":"103","author":"R Sun","year":"2016","unstructured":"Sun R, Shen S, Zhang YJ, Xu CF, Cao ZT, Wen LP, Wang J. Nanoparticle-facilitated autophagy Inhib promotes efficacy chemotherapeutics against breast cancer stem cells Biomaterials. 2016;103:44\u201355.","journal-title":"Nanoparticle-facilitated autophagy Inhib promotes efficacy chemotherapeutics against breast cancer stem cells Biomaterials"},{"issue":"7","key":"4316_CR153","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/vaccines13070767","volume":"13","author":"A Zahid","year":"2025","unstructured":"Zahid A, Ismail H, Wilson JC, Grice ID. Bioengineering Outer-Membrane Vesicles for Vaccine Development: Strategies, Advances, and Perspectives. Vaccines. 2025;13(7):767.","journal-title":"Vaccines"},{"key":"4316_CR154","doi-asserted-by":"crossref","unstructured":"Dong S et al. Experimental study on synergistic pulses improving the tumor microenvironment and assisting immunotherapy. Front Immunol, 2026. Volume 17\u20132026.","DOI":"10.3389\/fimmu.2026.1751463"},{"issue":"1","key":"4316_CR155","doi-asserted-by":"publisher","first-page":"10218","DOI":"10.1038\/s41467-024-54292-0","volume":"15","author":"J Qu","year":"2024","unstructured":"Qu J, Wang Y, Xiong C, Wang M, He X, Jia W, Shi P. In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy. Nat Commun. 2024;15(1):10218.","journal-title":"Nat Commun"},{"issue":"4","key":"4316_CR156","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/cancers17040701","volume":"17","author":"MA Rahman","year":"2025","unstructured":"Rahman MA, Jalouli M, Yadab MK, Al-Zharani M. Progress in drug delivery systems based on nanoparticles for improved glioblastoma therapy: addressing challenges and investigating opportunities. Cancers (Basel). 2025;17(4):701.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4316_CR157","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrmicro.2017.44","volume":"15","author":"L Zitvogel","year":"2017","unstructured":"Zitvogel L, Daill\u00e8re R, Roberti MP, Routy B, Kroemer G. Anticancer effects of the microbiome and its products. Nat Rev Microbiol. 2017;15(8):465\u201378.","journal-title":"Nat Rev Microbiol"},{"issue":"24","key":"4316_CR158","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1021\/acs.biochem.2c00251","volume":"61","author":"L Hamidi Nia","year":"2022","unstructured":"Hamidi Nia L, Claesen J. Engineered cancer targeting microbes and encapsulation devices for human gut microbiome applications. Biochemistry. 2022;61(24):2841\u20138.","journal-title":"Biochemistry"},{"issue":"1","key":"4316_CR159","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/imr.12856","volume":"295","author":"LM Sipe","year":"2020","unstructured":"Sipe LM, Chaib M, Pingili AK, Pierre JF, Makowski L. Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity. Immunol Rev. 2020;295(1):220\u201339.","journal-title":"Immunol Rev"},{"issue":"10","key":"4316_CR160","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/s41564-022-01226-5","volume":"7","author":"P Spanogiannopoulos","year":"2022","unstructured":"Spanogiannopoulos P, Kyaw TS, Guthrie BG, Bradley PH, Lee JV, Melamed J, Turnbaugh PJ. Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism. Nat Microbiol. 2022;7(10):1605\u201320.","journal-title":"Nat Microbiol"},{"issue":"1","key":"4316_CR161","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1021\/acsinfecdis.7b00166","volume":"4","author":"A Yan","year":"2018","unstructured":"Yan A, Culp E, Perry J, Lau JT, MacNeil LT, Surette MG, Wright GD. Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018;4(1):68\u201376.","journal-title":"ACS Infect Dis"},{"issue":"2","key":"4316_CR162","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3390\/biomedicines13020422","volume":"13","author":"AN Mafe","year":"2025","unstructured":"Mafe AN, B\u00fcsselberg D. Microbiome integrity enhances the efficacy and safety of anticancer drug. Biomedicines. 2025;13(2):422.","journal-title":"Biomedicines"},{"issue":"6","key":"4316_CR163","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.3390\/ijms24065978","volume":"24","author":"S Lozenov","year":"2023","unstructured":"Lozenov S, Krastev B, Nikolaev G, Peshevska-Sekulovska M, Peruhova M, Velikova T. Gut microbiome composition and its metabolites are a key regulating factor for malignant transformation, metastasis and antitumor immunity. Int J Mol Sci. 2023;24(6):5978.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4316_CR164","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41417-023-00715-x","volume":"31","author":"EF Giurini","year":"2024","unstructured":"Giurini EF, Godla A, Gupta KH. Redefining bioactive small molecules from microbial metabolites as revolutionary anticancer agents. Cancer Gene Ther. 2024;31(2):187\u2013206.","journal-title":"Cancer Gene Ther"},{"issue":"7882","key":"4316_CR165","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41586-021-04003-2","volume":"598","author":"FP Canale","year":"2021","unstructured":"Canale FP, Basso C, Antonini G, Perotti M, Li N, Sokolovska A, Geiger R. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature. 2021;598(7882):662\u20136.","journal-title":"Nature"},{"key":"4316_CR166","doi-asserted-by":"publisher","first-page":"113392","DOI":"10.1016\/j.intimp.2024.113392","volume":"144","author":"DY Sun","year":"2025","unstructured":"Sun DY, et al. Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies. Int Immunopharmacol. 2025;144:113392.","journal-title":"Int Immunopharmacol"},{"key":"4316_CR167","doi-asserted-by":"crossref","unstructured":"Amen RA, Hassan YM, Essmat RA, Ahmed RH, Azab MM, Shehata NR, El-Sayed WM. Harnessing the Microbiome: CRISPR-Based Gene Editing and Antimicrobial Peptides in Combating Antibiotic Resistance and Cancer. Probiotics and Antimicrobial Proteins, 2025: pp. 1\u201331.","DOI":"10.1007\/s12602-025-10573-8"},{"key":"4316_CR168","doi-asserted-by":"crossref","unstructured":"Feng X, Li Z, Liu Y, Chen D, Zhou Z. CRISPR\/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications. Volume 13. Experimental hematology & oncology; 2024. p. 102. 1.","DOI":"10.1186\/s40164-024-00570-y"},{"issue":"11","key":"4316_CR169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-025-03042-3","volume":"42","author":"AM Alamri","year":"2025","unstructured":"Alamri AM, Assiri AA, Khan B, Khan NU. Next-generation oncology: integrative therapeutic frontiers at the crossroads of precision genomics, immuno-engineering, and tumor microenvironment modulation. Med Oncol. 2025;42(11):1\u201320.","journal-title":"Med Oncol"},{"issue":"13","key":"4316_CR170","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.3390\/cancers17132163","volume":"17","author":"A Al-Kabani","year":"2025","unstructured":"Al-Kabani A, Huda B, Haddad J, Yousuf M, Bhurka F, Ajaz F, Banerjee Y. Exploring Experimental Models of Colorectal Cancer: A Critical Appraisal from 2D Cell Systems to Organoids, Humanized Mouse Avatars, Organ-on-Chip, CRISPR Engineering, and AI-Driven Platforms\u2014Challenges and Opportunities for Translational Precision Oncology. Cancers (Basel). 2025;17(13):2163.","journal-title":"Cancers (Basel)"},{"key":"4316_CR171","doi-asserted-by":"crossref","unstructured":"Allemailem KS, Alsahli MA, Almatroudi A, Alrumaihi F, Abdulmonem A, Moawad W, A. A., Khan AA. Innovative strategies of reprogramming immune system cells by targeting CRISPR\/Cas9-based genome-editing tools: a new era of cancer management. Int J Nanomed, 2023;18:5531\u201359.","DOI":"10.2147\/IJN.S424872"},{"key":"4316_CR172","doi-asserted-by":"crossref","unstructured":"Rahmati R, Zarimeidani F, Ghanbari Boroujeni MR, Sadighbathi S, Kashaniasl Z, Saleh M, Alipourfard I. CRISPR-Assisted Probiotic and In Situ Engineering of Gut Microbiota: A Prospect to Modification of Metabolic Disorders. Probiotics and Antimicrobial Proteins, 2025: pp. 1\u201317.","DOI":"10.1007\/s12602-025-10561-y"},{"issue":"4","key":"4316_CR173","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","volume":"43","author":"U Uslu","year":"2025","unstructured":"Uslu U, June CH. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat Biotechnol. 2025;43(4):506\u201315.","journal-title":"Nat Biotechnol"},{"key":"4316_CR174","doi-asserted-by":"publisher","first-page":"1335901","DOI":"10.3389\/fbioe.2023.1335901","volume":"11","author":"S Dixit","year":"2023","unstructured":"Dixit S, et al. Advancing genome editing with artificial intelligence: opportunities, challenges, and future directions. Front Bioeng Biotechnol. 2023;11:1335901.","journal-title":"Front Bioeng Biotechnol"},{"key":"4316_CR175","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ymben.2021.10.005","volume":"68","author":"K Kim","year":"2021","unstructured":"Kim K, et al. Engineering Bacteroides thetaiotaomicron to produce non-native butyrate based on a genome-scale metabolic model-guided design. Metab Eng. 2021;68:174\u201386.","journal-title":"Metab Eng"},{"issue":"7","key":"4316_CR176","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41564-024-01728-4","volume":"9","author":"N Quinn-Bohmann","year":"2024","unstructured":"Quinn-Bohmann N, et al. Microbial community-scale metabolic modelling predicts personalized short-chain fatty acid production profiles in the human gut. Nat Microbiol. 2024;9(7):1700\u201312.","journal-title":"Nat Microbiol"},{"issue":"2","key":"4316_CR177","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/crispr.2024.0058","volume":"8","author":"H Yuan","year":"2025","unstructured":"Yuan H, et al. An Overview and Comparative Analysis of CRISPR-SpCas9 gRNA Activity Prediction Tools. Crispr j. 2025;8(2):89\u2013104.","journal-title":"Crispr j"},{"issue":"Pt 2","key":"4316_CR178","doi-asserted-by":"publisher","first-page":"108703","DOI":"10.1016\/j.compbiolchem.2025.108703","volume":"120","author":"B He","year":"2026","unstructured":"He B, et al. Microbiome-transcriptome-histology triad enhances survival risk stratification in multiple cancers. Comput Biol Chem. 2026;120(Pt 2):108703.","journal-title":"Comput Biol Chem"},{"issue":"49","key":"4316_CR179","doi-asserted-by":"publisher","first-page":"12579","DOI":"10.1021\/acs.jpclett.5c03041","volume":"16","author":"K Huang","year":"2025","unstructured":"Huang K, et al. Machine Learning Accelerates Discovery of High-Performance Corrole Photosensitizers for Optical Imaging Diagnosis and Photodynamic Therapeutics of Nasopharyngeal Carcinoma. J Phys Chem Lett. 2025;16(49):12579\u201388.","journal-title":"J Phys Chem Lett"},{"key":"4316_CR180","doi-asserted-by":"crossref","unstructured":"Prusty P, Ray L. Advancements in cutaneous gene editing: The role of CRISPR technologies. 2025.","DOI":"10.61577\/amsd.2025.100001"},{"issue":"2","key":"4316_CR181","doi-asserted-by":"publisher","first-page":"108557","DOI":"10.1016\/j.cclet.2023.108557","volume":"35","author":"L Guo","year":"2024","unstructured":"Guo L, Ding J, Zhou W. Harnessing bacteria for tumor therapy: Current advances and challenges. Chin Chem Lett. 2024;35(2):108557.","journal-title":"Chin Chem Lett"},{"key":"4316_CR182","doi-asserted-by":"publisher","first-page":"49","DOI":"10.30683\/1927-7229.2025.14.09","volume":"14","author":"A Venkatesan","year":"2025","unstructured":"Venkatesan A, Sivanatham K. Immune Evasion and Resistance in Cancer Progression: Overcoming Checkpoint Inhibition Challenges with Personalized Immunotherapy Guided by PD-L1 Expression. J Anal Oncol. 2025;14:49\u201361.","journal-title":"J Anal Oncol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04316-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04316-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04316-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:03:01Z","timestamp":1781222581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04316-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":182,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4316"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04316-0","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper is submitted with the agreement of all its co-authors and the author list has been approved by all authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author agreement"}},{"value":"The authors declare that Gen AI and large language model (LLM) were used in the creation of this manuscript. Generative AI items like instatext, wordvice, and DeepL were used for structural editing and improve handwriting of the text.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}